https://patents.justia.com/patent/10150812
This week, the FDA approved a new treatment called teplizumab that delays the onset of type 1 diabetes.
TZIELD, the brand name, will total $193,000 over the 14-day treatment.
Experts say the new treatment could save patients years of taking insulin and monitoring blood sugar.
The Food and Drug Administration on Thursday approved the monoclonal antibody teplizumab, which will be sold under the brand name TZIELD, possibly saving patients like Olsten years of having to manage a costly and burdensome chronic disease.
Type 1 diabetes is an autoimmune disorder that causes the destruction of cells that secrete insulin from the pancreas, according to the British Diabetic Association, or Diabetes UK. It is different from Type 2 diabetes, which is caused when the body makes less insulin or becomes resistant to insulin, often because of excess body fat.
See Abomination List below..Including chimeric animal bindings, mRNA, and cDNA
The Tribulation is commencing..
Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.
#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus #Christ
Leave a Reply